Pioneers of the world’s first TCR therapy

We are a commercial-stage T cell receptor (TCR) biotechnology company that is pioneering and delivering transformative immunomodulating medicines to radically improve outcomes for patients living with cancer, infectious diseases, and autoimmune diseases.

Latest news

* Intended for investors and members of the media.

Latest Presentation

Corporate Presentation – June 2024

Latest Financial Results

Q1 2024

Quarter Ended Mar 31, 2024

Latest Annual Report

For Fiscal Year Ending Dec 31, 2023

Stock Snapshot

IR contacts


Immunocore Holdings plc
Immunocore Limited
92 Park Drive
Milton Park
Abingdon, Oxon OX14 4RY
T: +44 (0)1235 438600

Investor relations

Clayton Robertson
Head of Investor Relations
T: +1 (215) 384-4781

Transfer agent

Computershare Investor Services PLC
The Pavilions
Bridgwater Road
Bristol, BS99 6ZZ
United Kingdom
T: 0370 703 0387